(EAY 131-R MATCH): Phase II Study of Trametinib in Patients with BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations
Description: 
Frequency of non-V600 BRAF mutations Mutatations in BRAF at codons other than V600 (non-V600) have been identified in 2.79% of all tissue samples in the cBIO repository, a biorepository that includes 69 next generation sequencing studies across 23 histologic subtypes of cancer [8, 9]. These widely vary across cancer types, for example, in melanoma, approximately 5% of tumors harbor these mutations. These alterations are present in 1-3% of lung adenocarcinomas, and 1% or less of ovarian carcinomas, gastric carcinomas, prostate cancer, lung squamous cell carcinomas, glioblastomas,
Study Number: 

NCG 275215 R

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02465060

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.